KAPA — KAIROS PHARMA LTD

As of Q2 2026, 3 SEC-registered investment managers reported holding KAPA (KAIROS PHARMA LTD) in their latest 13F filings, with a combined reported value of $151.57K across 395.02K shares. That is +161.9% by share count (+244.18K shares) versus the previous quarter, while reported value moved +79.8%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.

Compared with the prior quarter, 2 opened new positions, 1 trimmed, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.

KAPA is classified in the Health Care sector.

All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.